#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## Form 8-K

#### **Current Report**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 13, 2019

# **CYTORI THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

Delaware

001-34375

33-0827593

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(I.R.S. Employer Identification Number)

3020 Callan Road, San Diego, California 92121 (Address of principal executive offices, with zip code)

(858) 458-0900

(Registrant's telephone number, including area code)

n/a

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  $\square$ 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  $\Box$ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  $\Box$ 

#### Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001	CYTX	Nasdaq Capital Market

#### Item 8.01 Other Events

On June 13, 2019, Cytori Therapeutics, Inc. (the "Company") issued a press release announcing it will provide a live webcast to discuss its continued transformation efforts following two recent asset sales and highlight key anticipated milestones on June 19, 2019 at 4:15 PM Eastern Time. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

### Item 9.01 Financial Statements and Exhibits

#### (d) Exhibits

<u>Exhibit No.</u>	Description
99.1	<u>Cytori Therapeutics, Inc. Press Release, dated June 13, 2019</u>

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### CYTORI THERAPEUTICS, INC.

Date: June 13, 2019

By: /s/ Gary Titus Gary Titus Chief Financial Officer

# Cytori to Present New Strategic Direction

Company to Announce New Therapeutic Area Focus and Brand Identity Plans

SAN DIEGO, June 13, 2019 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) "the Company" will provide a live webcast to discuss its continued transformation efforts following two recent asset sales and highlight key anticipated milestones on June 19, 2019 at 4:15 PM Eastern Time.

The dial-in information is as follows:

Dial-In Number: +1.877.402.3914

Conference ID: 9699923

Prior to the webcast, the Company will issue a press release containing pertinent information. The webcast will be available both live and by replay two hours after the call in the "Webcasts" section of the company's investor relations website.

Cytori Therapeutics, Inc.

Gary Titus, +1 858.458.0900

Email: ir@cytori.com

Website: http://ir.cytori.com